Skip Navigation LinksHome > March 2013 - Volume 26 - Issue 2 > Alternative pharmacologic targets for the treatment of schiz...
Current Opinion in Psychiatry:
doi: 10.1097/YCO.0b013e32835d8296
SCHIZOPHRENIA AND RELATED DISORDERS: Edited by W. Wolfgang Fleischhacker and Lynn E. DeLisi

Alternative pharmacologic targets for the treatment of schizophrenia: results from phase I and II trials

Miyamoto, Seiyaa; Jarskog, Lars F.b,c; Fleischhacker, W. Wolfgangd

Collapse Box


Purpose of review: The current article provides a brief review of the clinical efficacy and safety outcomes from selected phase I and II clinical trials of compounds in development acting on targets beyond the dopamine D2 receptor in patients with schizophrenia.

Recent findings: A number of experimental pharmacological targets have been studied in clinical trials. Among those, glutamatergic and nicotinergic pathways have received most attention. Glycine transporter 1 inhibitors used adjunctively with antipsychotics suggest efficacy for negative symptoms of schizophrenia. Adjunctive alpha7 nicotinic acetylcholine receptor agonists and minocycline may improve negative symptoms and cognitive deficits. Adjunctive oxytocin may benefit psychotic symptoms and social cognitive deficits. Adjunctive erythropoietin may improve cognitive function.

Summary: Experimental therapeutic research for schizophrenia is rapidly expanding and a number of compounds with novel mechanisms of action are demonstrating encouraging evidence for efficacy across a range of symptoms. However, much work still needs to be conducted before these new agents can be considered for routine clinical treatment. In particular, further assessment of efficacy and longer term safety and tolerability monitoring are required.

© 2013 Lippincott Williams & Wilkins, Inc.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.